tbuckley/cabot-search huggingface dataset:
Diagnostic indexes
Authors: R.J.G Chalmers
Journal: British Journal of Dermatology (1987)

Journal Article Diagnostic indexes Get access R.J.G Chalmers R.J.G Chalmers The Skin Hospital, Quay Street, Manchester M3 3HL, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 117, Issue 1, 1 July 1987, Page 134, https://doi.org/10.1111/j.1365-2133.1987.tb04106.x Published: 01 July 1987
The Ontario Air Pollution Study: Identification of the Causative Agent
Authors: D. V. Bates, R. Sizto
Journal: Environmental Health Perspectives (1989)

Previously published data from the Ontario Air Pollution study are reviewed. It has been shown that there is a consistent association in summer between hospital admissions for respiratory disease in Southern Ontario, and daily levels of SO4, O3, and temperature. No association exists for a group nonrespiratory conditions. Multiple regression analyses are presented that show all environmental variables account for 5.6% of the variability in respiratory admissions and that if temperature is forced into the analysis first, it accounts for 0.89% of the variability only. Distribution plots of standardized residuals are presented. In June of 1983, there were an exceptional number of ozone episodes (defined as occasions when ozone was greater than 82 ppb for 3 or more hours in a calendar day) in this region. A separate analysis of hospital admissions for acute respiratory diseases for the month of June for several years shows no demonstrable excess in June of 1983; previously regional analyses have indicated that ozone is associated with increased levels in July and August over a 9-year period. It has also been found that daily SO4 data collected at one monitoring site in the center of the region are not correlated with respiratory admissions, whereas the SO4 values collected every sixth day, on different days of the week, at 17 stations in the region had the highest correlation with respiratory admissions.(ABSTRACT TRUNCATED AT 250 WORDS)
PSYCHOTHERAPY
Authors: S.  KATZENELBOGEN
Journal: Annals of Internal Medicine (1944)

Article1 September 1944PSYCHOTHERAPYS. KATZENELBOGEN, M.D., F.A.C.P.S. KATZENELBOGEN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-21-3-412 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPsychotherapy may be defined as treatment by means which appeal to both intellectual and emotional functioning of the individual. It uses procedures which require special knowledge and training. In addition to, but also independently of such procedures, psychotherapy makes use of and is inadvertently influenced by factors involving the therapist, other persons in contact with the patient, and events affecting him. This definition implies that psychotherapeutic influences may be present in any medical treatment, in any relationship of the patient with others, in anything he is subjected to or comes in contact with, insofar as such varied relationships, things, and...Bibliography1. LEVINE M: Psychotherapy in medical practice, 1942, Macmillan Co., N. Y. CrossrefGoogle Scholar2. SCHILDER P: Psychotherapy, 1938, W. W. Norton Co., Inc., N. Y. Google Scholar3. DIETHELM O: Treatment in psychiatry, 1936, Macmillan Co., N. Y. CrossrefGoogle Scholar4. KATZENELBOGEN S: Iatrogenic factors in diseases, Dis. Nerv. System, 1941, ii, 342-345. Google Scholar5. RENNIE TA: Psychobiological therapy, Am. Jr. Psychiat., 1940, xcvii, 611-622. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Washington, D. C.*Received for publication August 17, 1943.†Clinical Professor of Psychiatry, George Washington University School of Medicine, Washington, D. C. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1944Volume 21, Issue 3Page: 412-420KeywordsEmotions ePublished: 1 December 2008 Issue Published: 1 September 1944 PDF downloadLoading ...
Abstract 1936: Label-free optical imaging and characterization of cancer-associated urinary extracellular vesicles: Implications for biomarker discovery
Authors: Ronit Barkalifa, Sixian You, Haohua Tu, Alison Masyr, Rebecca Kamerer, Marina Marjanovic, Jaena Park, Kimberly Selting, Stephen Boppart
Journal: Cancer Research (2019)

Abstract The discovery of extracellular vesicles (EVs) in all bodily fluids is rapidly increasing the fundamental knowledge of disease mechanisms and the ways in which cells communicate systemically to facilitate tumor progression and metastasis. The type, content, and magnitude of tumor-associated EVs have been linked to tumor invasiveness both in-vitro and in-vivo. In this study we utilized a novel label-free multimodal multiphoton optical imaging method to detect and characterize isolated urinary EVs and classify their optical signatures. Blinded analysis conducted on urinary EVs isolated from 4 healthy dogs and 19 dogs diagnosed with multiple types of cancer showed different optical signatures; cancer-associated urinary EVs were found to have significantly higher NADPH concentrations in comparison to those isolated from healthy dogs. These results suggest a potential label-free optical methodology to detect and characterize EVs by their optical signatures, which can be utilized as possible diagnostic and prognostic biomarkers for cancer. Citation Format: Ronit Barkalifa, Sixian You, Haohua Tu, Alison Masyr, Rebecca Kamerer, Marina Marjanovic, Jaena Park, Kimberly Selting, Stephen Boppart. Label-free optical imaging and characterization of cancer-associated urinary extracellular vesicles: Implications for biomarker discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1936.
Complications and Failures of Subclavian-Vein Catheterization
Authors: Paul F. Mansfield, David C. Hohn, Bruno D. Fornage, Mary Ann Gregurich, David M. Ota
Journal: New England Journal of Medicine (1994)

Although catheterization of the subclavian vein is a common procedure, the risk factors for complications and failures, with the exception of the physician's experience, are poorly understood. Ultrasonography has been recommended to help guide the placement of central venous catheters.
p53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia
Authors: Y Chen
Journal: Hepatology (2002)

Hepatocellular adenoma (HA) and focal nodular hyperplasia (FNH) are 2 rare, benign liver neoplasms that often are discovered incidentally. To date, few genetic changes have been found in these 2 benign lesions. However, the 2 pathways of p53 and Wnt signaling, which may be the most common molecular targets involved in liver tumorgenesis, were studied in HA and FNH. Ten HAs and 11 FNHs were analyzed for loss of heterozygosity (LOH) and sequencing analysis of mutation hot spots in exons 5 to 8 of the p53 gene. No LOH or mutant sequences were identified, indicating that p53 was not associated with these benign lesions. Genes in the Wnt signaling pathway, including β-catenin, axin, and adenomatous polyposis coli (APC), also were studied. Polymerase chain reaction (PCR) amplification and direct sequencing of all samples of HA and FNH displayed no mutations in exon 3 of the β-catenin gene. However, 3 HAs (30%) contained interstitial deletions from exon 3 to exon 4. Truncated forms of β-catenin detected by Western blot and immunohistochemical analyses showed they had accumulated in the cytoplasm and nuclei. However, for the axin and APC genes, no genetic changes, including allelic loss, interstitial deletions and point mutations, were detected in any of the HAs and FNHs. In conclusion, β-catenin, which participates in the Wnt signaling pathway, might play a more important role in the formation of HA than in that of FNH, but p53 is not associated with the development of either HA or FNH. (HEPATOLOGY 2002;36:927-935.)
"Modern" Medicine
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Most patients with low back pain have not recovered after a year
Journal: BMJ (1998)

Survival benefits of fibrinolysis and early aspirin in acute myocardial infarction are sustained Fibrinolytic therapy for patients with acute myocardial infarction has short term survival benefits, but information about long term effects is limited.Baigent et al (p 1337) report long term survival data from the ISIS-2 trial of intravenous streptokinase and one month's oral aspirin in suspected acute myocardial infarction.They found that the early survival benefits of fibrinolytic therapy persist for at least 10 years and do not seem to increase or decrease with prolonged follow up in any category of patients, including elderly patients.The survival benefits of aspirin also persist and are additional to those of fibrinolytic therapy.
NCCN News
Journal: Journal of the National Comprehensive Cancer Network (2020)

Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care CommunityNCCN recognizes the rapidly changing medical information relating to COVID-19 in the oncology ecosystem, but understands that a forum for sharing best practices and specific institutional responses may be helpful to others.Therefore, we are expeditiously providing documents and recommendations developed by NCCN Member Institutions or Guideline Panels as resources for oncology care providers.These resources have not been developed or reviewed by the standard NCCN processes, and are provided for informational purposes only.We will post more resources as they become available.Please check back for additional updates.
Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001).
Authors: M. Ueno, S. Ohkawa, K. Sugimori, S. Kobayashi, T. Kaneko, M. Taguri, S. Morita
Journal: Journal of Clinical Oncology (2011)

e14552 Background: Gemcitabine is still standard chemotherapy in pancreatic cancer. Pancreatic cancer patients often have cachexia with body weight loss. It had been reported that eicosapentaenoic acid (EPA) reduced proinflammatory cytokines, leading to improve inflammatory status of cachexia and attenuation of body weight loss in patients with advanced pancreatic cancer (Barber, et al, 1999).We hypothesized that EPA-enriched oral supplement may prevent cancer cachexia and prolong survival in advanced pancreatic cancer with chemotherapy. The aim of this randomized study is to evaluate the efficacy and safety of gemcitabine with an EPA enriched oral supplement compared with gemcitabine monotherapy in patients with unresectable advanced pancreatic cancer. Methods: This is a multicenter randomized phase II study. Patients will be randomized in a 2:1 ratio to Arm A or Arm B. In Arm A, 1,000mg/m2 of gemcitabine will be administered in a 30 minute intravenous infusion on days 1, 8, and 15. This cycle will be repeated every 4 weeks until disease progression. In addition, a maximum of 2 packs of an EPA-enriched oral supplement (Prosure, Abbott) will be administered every day. Arm B patients will receive gemcitabine monotherapy. Major inclusion criteria include patients over 20 years old with recurrent or unresectable pancreatic cancer that is histologically verified, an ECOG PS of 0,1 or 2, sufficient oral intake. The primary endpoint is the evaluation of 1-year survival. The secondary endpoints are progression-free survival, response rate, adverse events, QOL evaluation, body weight and performance status. A sample size of 66 patients was chosen on the basis of the randomized phase II selection design by Simon et al (1985). The design has a 78% correct selection probability if 1-year survival probabilities are 35% and 25% for two treatment arms. To date, 34 patients have been enrolled.
Tratamiento moderno de las anemias
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Economics
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abnormally large von Willebrand factor multimers in Henoch‐Schönlein purpura
Authors: Alessandra Casonato, Elena Pontara, Antonella Bertomoro, Elena Ossi, Massimo Vincenti, Antonio Girolami, Arturo Borsatti, Giselda Bertaglia
Journal: American Journal of Hematology (1996)

Allergic vasculitis phenomena seem to be involved in Henoch-Schönlein purpura (HSP). Elevated plasma levels of von Willebrand factor (vWf) are a well recognized feature of vasculitis and have been taken as an indication of in vivo endothelial cell damage. Plasma factor VIII:C and vWf levels and vWf multimeric pattern were studied in 8 patients with HSP, during active disease and twice during the remission (3 and 9 months later). Plasma vWf multimeric composition was evaluated using low resolution gels which better resolve large vWf multimers. During active disease plasma factor VIII:C, vWf:Ag, and vWf:RCoF were normal in 5% of patients and increased in three, but in each patient, platelets appeared to aggregate at doses of ristocetin lower than in normals. Furthermore, all patients demonstrated the presence of abnormally large vWf multimers usually found only in platelets and endothelial cells. Three and 9 months later, during remission, in spite of the normalization of factor VIII:C and vWf levels, the abnormal multimers were still detectable, as well as hyper-responsiveness to ristocetin. These findings confirm that damage and/or perturbation of endothelial cells is associated with HSP. Moreover, the persistence of abnormality in the vWf multimeric pattern, when the disease is inactive, suggests that the mechanisms involved operate through the entire clinical course. © 1996 Wiley-Liss, Inc.
Acta Oto-Laryngologica, Stockholm
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopy
Authors: Edward B. Benedict
Journal: New England Journal of Medicine (1947)

Gastroscopy Instruments Six years ago Kenamore described a biopsy forceps for the flexible gastroscope. In a study of gastric lesions by means of biopsy specimens removed endoscopically, Kenamore, Scheff and Womack46 presented 4 cases illustrating the value of the instrument as a positive method of differentiating benign and malignant gastric lesions. The instrument, which in trained hands is regarded as safe and as offering a method of more exact study of gastric diseases, is a flexible steel cable of fine caliber that can be attached externally to the gastroscope, whose diameter is thereby increased by only 3 mm. There is . . .
Abstract MP63: Fat Quality Estimated by Computed Tomography and Associations with Incident Cardiovascular Disease and All Cause Mortality
Authors: Klara J Rosenquist, Joseph M Massaro, Bernard E Krieger, Joanne M Murabito, Udo Hoffmann, Caroline S Fox
Journal: Circulation (2013)

Background: Computed tomography (CT) attenuation of abdominal fat as measured by Hounsfield units (HU) is associated with the composition of fat such as adipocyte size, vascularity, and fibrosis and has been associated with varying degrees of cardiometabolic risk. The objective of this study was to determine if fat quality, evaluated by CT attenuation of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), is prospectively associated with incident cardiovascular disease (CVD) and all cause mortality outcomes independent of absolute VAT and SAT volumes. Methods: Participants were drawn from offspring and third-generation cohorts from the multidetector computed tomography sub-study of the Framingham Heart Study (n=3324, 48% women, mean age of 51 years). SAT and VAT volumes were acquired by manually outlining the abdominal muscular wall separating the visceral from the subcutaneous fat depot. The average HU of each depot were recorded. Cardiovascular risk factors were measured using standard definitions. The outcomes of interest were incident CVD, all cause mortality, non-cardiovascular deaths and cancer deaths. Information on cause of death was obtained from death certificates, medical records and family members. Cox proportional hazard models were used to determine the association between VAT and SAT HU and the outcomes of interest. We adjusted for standard CVD risk factor covariates, secondarily for BMI, and then for VAT or SAT volumes. Results: There were a total of 111 incident CVD events, 85 deaths including 69 non-cardiovascular deaths and 45 cancer deaths in up to 23,047 person-years of follow-up. A one standard deviation (SD) increment in VAT attenuation was associated with a multivariable adjusted hazard ratio (HR) for all cause mortality of 1.40 (95% CI 1.12-1.75, p=0.003), which was strengthened after additional adjustment for BMI (HR 1.53, 95% CI 1.21-1.93, p&lt;0.001) and VAT volume (HR 1.99, 95% CI 1.47-2.69, p&lt;0.001). Non-cardiovascular death accounted for the majority of this trend and remained significant in all three models, including after adjustment for VAT volume (HR 1.97, 95% CI 1.42-2.75, p&lt;0.001). More specifically VAT HU was associated with cancer deaths (HR 1.96, 95% CI 1.29-2.98, p=0.001). Conversely, we observed no association between VAT HU and incident CVD in the multivariable model (HR 0.83, 95% CI (0.67, 1.04) p=0.11) or after additional adjustment for BMI or VAT volume. Similar results were found for SAT HU. Conclusions: CT attenuation of both VAT and SAT is associated with all-cause mortality, non-cardiovascular death and cancer death. These associations highlight how indirect indices of fat quality can potentially add to our understanding of the complications of obesity.
Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis
Authors: Brian A Walker, Dorota Rowczienio, Eileen M Boyle, Christopher P Wardell, Sajitha Sachchithanantham, Anna Baginska, Julian D Gillmore, Shameem Mahmood, Helen J Lachmann, Philip N Hawkins, Faith E Davies, Gareth J Morgan, Ashutosh Wechalekar
Journal: Blood (2013)
Hope hype hit
Authors: G. Radulescu
Journal: JAMA (1990)

<h3>In Reply.—</h3> Drs Fried and Appel state that requiring independent samples to compare performance characteristics unnecessarily doubles the sample size. We do state that independent samples are needed to retain mathematical correctness, because the 2 × 2 contingency configurations on which our tables are based are modeled on independent samples. In practice, however, using paired data in a 2×2 contingency table is equivalent to using independent data and equally efficient. One only sacrifices the opportunity for further statistical efficiency. Therefore, we maintain that the sample size requirements (SSRs) of 67 obtained in our exercise 1 need not be doubled. Their other concern is our failure to minimize SSRs through paired analysis where one considers only the discordant data pairs, ie, those results positive by method A and negative by method B or vice versa. If methods A and B are independent of one another, paired analysis neither increases statistical power